MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 11.08.2022
Affimed N.V. Langfristiger Schuldenstrom 2011-2026 | AFMD
Langfristiger Schuldenstrom Jährlich Affimed N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 492 K | 532 K | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 532 K | 492 K | 512 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 215.54 | -1.16 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 3.88 | -1.27 % | $ 415 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 19.23 | - | $ 899 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 8.18 | -2.97 % | $ 109 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
440 K | $ 0.71 | 17.15 % | $ 8.13 M | Israel |
 |
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.32 | -5.71 % | $ 337 M |  Britain |
 |
CytomX Therapeutics
CTMX
|
4.24 M | $ 4.24 | -4.83 % | $ 585 M | USA |
 |
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | USA |
 |
Genmab A/S
GMAB
|
26 M | $ 25.81 | 0.51 % | $ 16.6 B | Danmark |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.65 | 0.76 % | $ 16.6 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | USA |
 |
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Eton Pharmaceuticals
ETON
|
65 K | $ 22.97 | -3.53 % | $ 618 M | USA |
 |
Exelixis
EXEL
|
27.9 M | $ 41.57 | 0.39 % | $ 11.3 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
Fortress Biotech
FBIO
|
2.62 M | $ 2.92 | -2.01 % | $ 60.7 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
547 K | $ 4.31 | -2.49 % | $ 826 M | Canada |
 |
Homology Medicines
FIXX
|
693 K | - | 0.77 % | $ 53.4 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |